Chulani joined Maverick Therapeutics as SVP, Technical Operations in July 2019. Chulani is responsible for all CMC aspects including process development, technology transfer, GMP manufacturing, analytical and quality control.
Chulani has over 30 years of experience in the biopharmaceutical industry working with pioneering monoclonal antibodies (mAbs), conjugated proteins and vaccines and has contributed to the successful development and commercialization of several mAbs including including Rituxan® (rituximab), Herceptin® (trastuzumab), Xolair® (omalizumab), Vectibix® (panitumumab) and Menjugate® vaccine. Prior to joining Maverick, Chulani was SVP of Pharmaceutical Development and Manufacturing at Nektar Therapeutics where he was responsible for building the biologics CMC capabilities for Nektar’s polymer conjugated cytokine franchise. Prior to Nektar, Chulani held positions of increasing responsibility at Amgen, Novartis, Genentech and Eli Lilly.
Chulani received his B.Sc. (Honors) in Chemistry from University of Colombo, Sri Lanka, and his Ph.D. in Chemistry/Biochemistry from University of Illinois, Chicago.